Abstract:Ferroptosis, a form of regulated cell death that is induced by excessive lipid peroxidation, is a key tumour suppression mechanism<a href="#ref-CR1">1</a>,<a href="#ref-CR2">2</a>,<a href="#ref-CR3">3</a>,<a href="/articles/s41586-021-03539-7#ref-CR4">4</a>. Glutathione peroxidase 4 (GPX4)<a href="/articles/s41586-021-03539-7#ref-CR5">5</a>,<a href="/articles/s41586-021-03539-7#ref-CR6">6</a> and ferroptosis suppressor protein 1 (FSP1)<a href="/articles/s41586-021-03539-7#ref-CR7">7</a>,<a href="/articles/s41586-021-03539-7#ref-CR8">8</a> constitute two major ferroptosis defence systems. Here we show that treatment of cancer cells with GPX4 inhibitors results in acute depletion of N-carbamoyl-l-aspartate, a pyrimidine biosynthesis intermediate, with concomitant accumulation of uridine. Supplementation with dihydroorotate or orotate—the substrate and product of dihydroorotate dehydrogenase (DHODH)—attenuates or potentiates ferroptosis induced by inhibition of GPX4, respectively, and these effects are particularly pronounced in cancer cells with low expression of GPX4 (GPX4low). Inactivation of DHODH induces extensive mitochondrial lipid peroxidation and ferroptosis in GPX4low cancer cells, and synergizes with ferroptosis inducers to induce these effects in GPX4high cancer cells. Mechanistically, DHODH operates in parallel to mitochondrial GPX4 (but independently of cytosolic GPX4 or FSP1) to inhibit ferroptosis in the mitochondrial inner membrane by reducing ubiquinone to ubiquinol (a radical-trapping antioxidant with anti-ferroptosis activity). The DHODH inhibitor brequinar selectively suppresses GPX4low tumour growth by inducing ferroptosis, whereas combined treatment with brequinar and sulfasalazine, an FDA-approved drug with ferroptosis-inducing activity, synergistically induces ferroptosis and suppresses GPX4high tumour growth. Our results identify a DHODH-mediated ferroptosis defence mechanism in mitochondria and suggest a therapeutic strategy of targeting ferroptosis in cancer treatment.

Diazepam-based covalent modifiers of GPX4 induce ferroptosis in liver cancer cells

Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis in Vivo.

A Chiral Fluorescent Ir(iii) Complex That Targets the GPX4 and ErbB Pathways to Induce Cellular Ferroptosis.

Exploiting Cancer Vulnerabilities by Blocking of the DHODH and GPX4 Pathways: A Multifunctional Bodipy/PROTAC Nanoplatform for the Efficient Synergistic Ferroptosis Therapy

DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer

Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles

Diaryl ether derivative inhibits GPX4 expression levels to induce ferroptosis in thyroid cancer cells

ZX703: A Small-Molecule Degrader of GPX4 Inducing Ferroptosis in Human Cancer Cells

Recent Progress of Glutathione Peroxidase 4 Inhibitors in Cancer Therapy

Research progress on GPX4 targeted compounds

Forward Chemical Genetic Screen for Oxygen‐Dependent Cytotoxins Uncovers New Covalent Fragments that Target GPX4

Discovery of Novel Potent Covalent Glutathione Peroxidase 4 Inhibitors as Highly Selective Ferroptosis Inducers for the Treatment of Triple-Negative Breast Cancer

A Potent and Selective Anti-Glutathione Peroxidase 4 Nanobody as Ferroptosis Inducer

Novel Allosteric Activators for Ferroptosis Regulator Glutathione Peroxidase 4.

Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells

In vivo assembly enhanced binding effect augments tumor specific ferroptosis therapy

Ferroptosis Mediated Novel Drug Design Approach in the Treatment of Oral Squamous Cell Carcinoma

GPX4 allosteric activators inhibit ferroptosis and exert myocardial protection in doxorubicin-induced myocardial injury mouse model

Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells

Design, Synthesis, and Biological Evaluation for First GPX4 and CDK Dual Inhibitors

A potent GPX4 degrader to induce ferroptosis in HT1080 cells